Dr. Ajaykumar Rao Provides Perspective to Medscape on Eli Lilly Offering Expanded Access to Weight-Loss Drug Retatrutide

Ajaykumar D. Rao, MD, MMSc, FACP, Chief of the Section of Endocrinology, Diabetes and Metabolism at the Lewis Katz School of Medicine at Temple University, provided perspective to Medscape about Eli Lilly offering expanded access to retatrutide, its investigational triple hormone receptor agonist that has demonstrated substantial weight loss in phase 3 studies.